Biopharma just invested $270 million in hair loss. Here is what that money is buying — and what it isn't.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
7:30
From Root to Ritual by Laritelle Organic.
Something significant is happening in the hair loss pharmaceutical landscape. In late 2025, investor enthusiasm around hair loss therapies reached a new peak — Pelage Pharmaceuticals raised $120 million, Veradermics secured $150 million, and the question being asked across biopharma was whether hair loss could be the next GLP-1 moment: a category that had been chronically underfunded suddenly rece...
Read the full article: https://laritelleorganic.com/blogs/news/biopharma-just-invested-270-million-in-hair-loss-here-is-what-that-money-is-buying-and-what-it-isnt
Something significant is happening in the hair loss pharmaceutical landscape. In late 2025, investor enthusiasm around hair loss therapies reached a new peak, Pelage Pharmaceuticals raised $120 million, Viridermix secured $150 million, and the question being asked across Biopharma was whether hair loss could be the next GLP1 moment, a category that had been chronically underfunded, suddenly receiving the scientific attention and capital it deserved. The comparison is not superficial. GLP1 agonists succeeded because the science finally caught up with a biological mechanism that was always there. The incretin system had been studied for decades before semaglutide turned it into the defining drug class of the 2020 S. Hair loss research is experiencing the same inflection point. The follicle stem cell biology, the circadian mechanisms, the energy metabolism pathways, the microbiome connections, all of it has been accumulating in the research literature for years. The Capital is finally following the science, PP 405, which presented updated data at the American Academy of Dermatology 2026 annual meeting, is moving toward phase 3 trials. Clascoderone has completed phase 3 with a 539% relative improvement versus placebo and is moving toward regulatory submission. VDPHL01 has phase 3 data and $150 million behind it. The pipeline is real, the results are serious, and they are years away from your bathroom cabinet. What the pipeline delivers. The four mechanisms Biopharma is betting on, and what each addresses. PP405, follicle energy metabolism, phase 3, 2026, PP405 targets, the mitochondrial pyruvate carrier, changing how follicle cells produce energy, moving from stem cell research to clinical application, with the potential to redefine therapeutic strategies for hair loss through a regenerative, mechanism-driven approach. At AAD 2026, the data confirmed that follicular unit activation, the natural groupings of 1 to 5 follicles, is a more clinically meaningful efficacy measure than hair counts alone. Even in areas of apparent hair loss, stem cells often remain present but inactive. PP405 aims to regenerate terminal hair growth from previously dormant follicles. What it addresses, cellular energy metabolism, the PP405 mechanism we covered in May. What it doesn't address, DHT, inflammation, microbiome, circadian disruption, collagen decline, clascoterone, topical DHT receptor blockade, regulatory submission 2026. As we covered yesterday, 539% relative improvement in hair count versus placebo across 1,465 men. The first topical DHT blocker designed specifically for the scalp. Clascoderone is the most advanced of the newer treatments and may become a useful topical option, particularly for women. But it is not a cure and is unlikely to replace existing treatments. That honest clinical assessment from the researchers themselves is important. A single pathway DHT blocker, however effective on that pathway, leaves the other five drivers running. What? It addresses DHT at the androgen receptor, locally without systemic effects. What it doesn't address energy metabolism, inflammation, microbiome, circadian, collagen. VDPHL01, oral systemic delivery, phase 3 complete. 30 to 33 additional hairs per square centimeter over six months versus seven in the placebo group. An oral delivery mechanism that confirms the bloodstream is the right route to the follicle, which we covered in the May VDPHL-01 article. The mechanism is not yet fully published, which means its interaction with other drivers is unknown. Durability, real-world effectiveness, and long-term safety are still unknown for all of these newer treatments. What it addresses, systemic delivery of an unknown mechanism, results confirmed, biology still being mapped, what it doesn't address, cannot be determined until the mechanism is published. ET02 and GT2029, next generation, phase 1-2, ET02, Arian Therapeutics, corrects defective follicle stem cells. GT2029, Kintor, is a topical androgen receptor degrader, going further than clascoterone, by not just blocking but degrading the androgen receptor in scalp tissue. Both are earlier stage with limited published data. PP405 and ET02 are very early, and the level of online excitement surrounding them is far ahead of the actual data. The caution from clinical experts is warranted. Phase 1. Two results are mechanistic signals, not efficacy confirmation at scale. Timeline. Realistic approval for leading candidates is 2027-2028. $270 million raised by Pellage and Veridermics alone in late 2025, the largest single-year capital deployment into hair loss pharmaceuticals in history, 2027, 28 earliest realistic approval timeline for leading candidates, Class Coderone, PP405, and VDPHL01, assuming smooth regulatory review, one of six primary drivers addressed by each individual drug in the pipeline, the multidriver biology of hair loss remains incompletely covered by any single pharmaceutical, the honest assessment, what $270 million cannot buy, and what fills the gap. Hair loss is not one disease, it is a set of conditions with different drivers, so one breakthrough rarely helps everyone. This observation from the research community is the most important context for reading the pipeline news. Each drug in development addresses one or two of the six primary biological drivers this month's articles have mapped. None addresses all six, none is designed to. Driver Pipeline Coverage Available Now, DHT slash androgen receptor, clascoterone, topical. 2027 plus Bringarage, Nettle, Saw Palmetto, Topical, Daily Follicle Energy Metabolism, PP405, Phase 3, 2027 Plus Ginger, ATP, Rosemary, Mitochondrial, Massage, Circulation, Systemic Multipathway, VDPHL, 01 Oral. 2027 Plus Daily Botanical Ritual via Transdermal Plus Systemic Absorption. Pillif inflammation. No pipeline candidate specifically targeting this patchouli lavender, clove bud, pH balanced shampoo, daily scalp microbiome, no pip.